Genomics company Biofidelity has announced the launch of Aspyre Lung reagents for liquid biopsy samples. Aspyre Lung identifies established non-small cell lung cancer (NSCLC) biomarkers in both DNA and RNA from tissue and blood in a single straightforward, four-step workflow and runs on existing qPCR platforms, enabling simple integration into laboratories globally.
“Until now there has not been an alternative to next-generation sequencing (NGS) to provide fast, simple, decentralised testing for NSCLC biomarkers,” said Biofidelity Co-Founder and CEO Barnaby Balmforth PhD. “Aspyre Lung’s best-in-class performance from tissue and blood coupled with its proven performance with challenging samples makes Simplified Genomic Profiling (SGP) via Aspyre Lung a game-changer for laboratories globally.”
Data supporting the launch will be presented at the Association for Molecular Pathology Annual Meeting & Expo (AMP24) 19-23 November, 2024 in Vancouver, Canada.
At AMP24 Biofidelity will host an Innovation Spotlight entitled ‘Aspyre Lung: Simplified Genomic Profiling: A faster, simpler, decentralized alternative to NGS’, presented by Dr Jeff Gregg, Biofidelity’s Vice President of Medical Affairs. “An accessible liquid biopsy platform that can be easily validated and implemented in laboratories globally without the need for investment in new equipment and bioinformatics will undoubtedly lead to a fundamental paradigm shift enabling broader access to genomic testing,” said Dr Gregg.
Aspyre Lung reagents are currently research use only.
To learn more about Aspyre Lung, please visit biofidelity.com